Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial

AIMS: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate against human epidermal growth factor receptor 2 (HER2), has been used in the treatment of patients with HER2-positive metastatic breast cancer (MBC). We conducted a meta-analysis to evaluate the efficacy and toxicity of T-DM1 for the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hongjing, Yu, Kewei, Zhang, Kaile, Liu, Linxia, Li, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731971/
https://www.ncbi.nlm.nih.gov/pubmed/29254261
http://dx.doi.org/10.18632/oncotarget.22270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731971/
https://www.ncbi.nlm.nih.gov/pubmed/29254261
http://dx.doi.org/10.18632/oncotarget.22270

Ejemplares similares